Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial
King of Prussia, Pennsylvania--(Newsfile Corp. - January 20, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio an
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-20 9:30 AM EST | Phio Pharmaceuticals Corp.
Functional Brands Inc. Introduces Kirkman(R) Detox Aid Bundle: a Comprehensive Approach to Heavy Metal and General Detoxification Support
Lake Oswego, Oregon--(Newsfile Corp. - January 20, 2026) - Functional Brands Inc. (NASDAQ: MEHA), a leading innovator in wellness and performance products, today announced the launch of its Kirkman's Detox Aid bundle, designed to provide foundational support for detoxification-especially targeting heavy metals and environmental toxins. This innovative combination includes Detox Aid with key ingredients such as glutathione, olive leaf, selenium, and alpha-ketoglutarate (AKG), alongside
Household / Consumer / Cosmetics, Health
2026-01-20 8:00 AM EST | Functional Brands Inc.
BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)
Vancouver, British Columbia--(Newsfile Corp. - January 20, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, in
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-20 8:00 AM EST | BioVaxys Technology Corp.
Akanda Announces $7.0 Million Convertible Note Offering
Toronto, Ontario--(Newsfile Corp. - January 20, 2026) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company") today announced the execution of a securities purchase agreement with institutional investors for the purchase and sale of 12 month, convertible promissory notes for an aggregate purchase price of $7.0 million, in a private placement transaction. The closing of the transaction is expected to occur, subject to customary closing conditions, on January 21, 2026. The Com
Cannabis, Health, Cannabis Cultivator, Cannabis Manufacturer
2026-01-20 8:00 AM EST | Akanda Corp
Safe Supply Announces Sale of NIRLAB Drug Analysis Device to Far North Resources Inc., Advancing Indigenous-Led Community Safety and Rapid Drug Identification
Toronto, Ontario--(Newsfile Corp. - January 20, 2026) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (OTCQB: SSPLF) (FSE: QM4) ("Safe Supply" or the "Company"), a pioneer in health, safety and rapid response technologies, today announced the sale of a NIRLAB SA ("NIRLAB") NIRLIGHT spectroscopy drug analysis device to Far North Resources Inc., representing the first transaction completed under Safe Supply's exclusive Canadian distribution agreement with NIRLAB, and rei
2026-01-20 7:04 AM EST | Safe Supply Streaming Co Ltd.
Therma Bright Sells an Additional 200-Units of Venowave(TM) to Strategic Distribution Partner Gen-X Med
Toronto, Ontario--(Newsfile Corp. - January 20, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma Bright" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce it has received a follow-on order for an additional 200 Venowave™ VW5 units from its Texas-based distribution partner, Gen-X Med. This latest transaction marks the expansion of the relationship between the
Technology, Biotechnology, Health
2026-01-20 6:30 AM EST | Therma Bright Inc.
Relief AI Assisting World Class Athletes in Mental Preparation For 2026 Olympic Winter Games
Toronto, Ontario--(Newsfile Corp. - January 19, 2026) - Relief AI Inc. (the "Company "or "Relief AI") (www.reliefai.ca), developer of the leading-edge workplace well-being platform naia, which identifies and assists professionals address early signs of workplace burnout, is proud to announce its sponsorship of World Cup Champion and Olympic hopeful Johannes "Hansi" Lochner, Germany's elite bobsleigh athlete. A
Technology, Healthcare and Hospitals, Health
2026-01-19 7:00 AM EST | Relief AI Inc.
DiagnosTear Announces Interim Clinical Results Indicating High Efficiency from TeaRx(TM) Red Eye
Vancouver, British Columbia--(Newsfile Corp. - January 16, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care ocular diagnostics, today announced highly encouraging interim results from its ongoing multi-center Israeli clinical study supporting the development of its TeaRx™ Red Eye diagnostic platform. TeaRx™ Red Eye is being developed as the first rapid, multi-biomarker, point-of-car
2026-01-16 7:00 PM EST | DiagnosTear Technologies Inc.
NuGen Medical Devices Provides 2025 Year End Update on R&D and Strategic Progress
Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a leader in needle-free subcutaneous drug-delivery technology, is providing a summary of key developments achieved during 2025 across its Research and Development programs, technical capabilities, clinical initiatives, and global commercial activities. 2025 Operational Highlights Research & Development Demonstrate
Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-16 5:30 PM EST | NuGen Medical Devices Inc.
Hemostemix Receives FDA Support for Its Basket Protocol Approach
Calgary, Alberta--(Newsfile Corp. - January 16, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, and vascular dementia, in Florida, Canada, The Bahamas, announces the successful completion of its pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administra
Biotechnology, Pharmaceuticals, Health
2026-01-16 12:26 PM EST | Hemostemix Inc.
LIS Technologies Inc. to Invest $1.38 Billion in Oak Ridge, Tennessee Following Its Acquisition of $8 Million, 206-Acre Duct Island, Now Rebranded as "LIST Island"
Oak Ridge, Tennessee--(Newsfile Corp. - January 16, 2026) - LIS Technologies Inc. ("LIST" or "the Company"), a proprietary developer of advanced laser technology and the only USA-origin and patented laser uranium enrichment company, alongside Tennessee Gov. Bill Lee and Deputy Gov. and Department of Economic and Community Development Commissioner Stuart C. McWhorter, today announced LIST will create 203 jobs and invest $1.38 billion in its future flagship commercial scale laser-
Technology, Mining and Metals, Energy, Health
2026-01-16 10:07 AM EST | LIS Technologies Inc.
Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has entered into an agreement with a sole underwriter and sole bookrunner pursuant to which the underwriter (the "Underwriter") has agreed to purchase for resale 10,384,616
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2026-01-16 8:46 AM EST | Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has entered into an agreement with Canaccord Genuity Corp. (the "Underwriter") as the sole underwriter and sole bookrunner pursuant to which the Underwriter has agreed to p
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2026-01-16 8:42 AM EST | Cardiol Therapeutics Inc.
Optimi Health Announces Equity Incentive Grants and Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - January 16, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA and psilocybin, today announced a series of equity compensation and marketing initiatives designed to support its growth strategy and enhance market awareness. Equity Incentive Grants Optimi announces that, pursuant to its equity incentive plan and subject
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-01-16 7:00 AM EST | Optimi Health Corp.
Psyched Wellness Sells Out of First Run of Calmer and Announces New Production Run
Toronto, Ontario--(Newsfile Corp. - January 15, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) ("Psyched" or the "Company"), a life sciences company dedicated to developing and commercializing products derived from the Amanita Muscaria mushroom, is pleased to announce a key commercial milestone for its newest product, Calmer. The Company has officially sold out of its initial production run following strong early demand and positive consumer feedback.
Cannabis, Health, Psychedelics, Cannabis Manufacturer
2026-01-15 12:42 PM EST | Psyched Wellness Ltd.
Adia Nutrition Promotes Emmanuela Derisbrun, APRN, FNP-C, to Provider Role Amid Growing Patient Demand and Launch of Autism IRB Study
Winter Park, Florida--(Newsfile Corp. - January 15, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), through its medical division Adia Med specializing in advanced regenerative therapies, announces that Emmanuela Derisbrun, APRN, FNP-C, has transitioned from subcontractor to employed provider. This move supports rising patient volume and the launch of Adia Med's IRB-approved autism spectrum disorder regenerative study.
Healthcare and Hospitals, Health
2026-01-15 11:03 AM EST | Adia Nutrition Inc.
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - January 15, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical t
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-15 8:45 AM EST | Phio Pharmaceuticals Corp.
Predictmedix AI Inc. Selected by Canadian Government for Mexico Trade Mission, Led by Minister Dominic LeBlanc, to Drive Growth and High-Value Partnerships
Toronto, Ontario--(Newsfile Corp. - January 15, 2026) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or the "Company"), a pioneering leader in artificial intelligence-enabled health and safety technology, proudly announces its highly selective inclusion in the Official Canada Trade Mission to Mexico, scheduled for February 15–20, 2026, with key activities centered in Mexico City, Guadalajara, and Monterrey. This elite delegation brings together on
2026-01-15 7:03 AM EST | QScreen AI Inc.
Scryb Inc. Provides Early Warning Update on Holdings in Cybeats Technologies Corp.
Toronto, Ontario--(Newsfile Corp. - January 14, 2026) - Scryb Inc. (CSE: SCYB) (OTCQB: SCYRF) ("Scryb'' or the "Company"), is issuing this release to report information concerning its holdings in Cybeats Technologies Corp. (the "Issuer" or "Cybeats"). Scryb's total share ownership position of Cybeats is unchanged following all transactions outlined in this press release. Scryb outlines below that it accepted common shares in lieu of cash repayment from Cybeats Techno
Biotechnology, Healthcare and Hospitals, Health
2026-01-14 9:08 PM EST | Scryb Inc.
LIS Technologies Inc. Appoints 25 Year Plus Veteran and Distinguished U.S. National Laboratory Leader Dr. Kirk D. Rector as Director of its Medical and Stable Isotopes
Oak Ridge, Tennessee--(Newsfile Corp. - January 14, 2026) - LIS Technologies Inc. ("LIST" or "the Company"), a proprietary developer of advanced laser technology and the only USA-origin and patented laser uranium enrichment company, today announced that Kirk D. Rector, Ph.D., has been appointed as its Director of Medical and Stable Isotopes. Dr. Kirk D. Rector is a physical chemist and technology leader with more than twenty-five years of experience spanning medical and stable is
Technology, Mining and Metals, Energy, Health
2026-01-14 8:29 AM EST | LIS Technologies Inc.